Abstract
Background Alterations of the gut microbiota after allogeneic hematopoietic cell transplantation (allo-HCT) are a key factor in the development of transplant-related complications such as graft-versus-host disease (GVHD). Interventions that preserve the gut microbiome hold promise to improve HCT-associated morbidity and mortality. Murine models demonstrate that prebiotics such as fructo-oligosaccharides (FOS) may increase gut levels of short-chain fatty acids (SCFAs) such as butyrate, and consequently induce proliferation of immunomodulatory CD4+ FOXP3+ T-regulatory cells (Tregs), that impact GVHD risk.
Methods We conducted a pilot Phase I trial to assess the investigate the maximum tolerated dose of FOS in patients undergoing reduced-intensity (RIC) allo-HCT (n=15) compared to concurrent controls (n=16). We administered FOS starting at pretransplant conditioning and continuing for a total of 21 days. We characterized the gut microbiome using shotgun metagenomic sequencing, measured stool SCFAs using LC-MS, and determined peripheral T-cell concentrations using CyTOF.
Results We found that FOS was safe and well-tolerated at 10g per day without significant adverse effects in patients undergoing reduced-intensity conditioning allo-HCT. Community-level gut microbiota composition was significantly different on the day of transplant (day 0) between patients receiving FOS compared to concurrent controls, however FOS-associated alterations of the gut microbiota were not sustained after transplant. Although the impact of FOS was fleeting, transplantation itself impacted a substantial number of taxa over time. In our small pilot trial, no significant differences were observed in gut microbial metabolic pathways, stool SCFAs, or in peripheral Tregs although Tregs trended higher in those patients who received FOS. Early alterations in gut microbiota composition in those receiving FOS are especially intriguing although it remains unclear what impact this has on outcomes following transplantation and larger studies are required to investigate the use of prebiotics in HCT recipients.
Conclusions FOS is well-tolerated at 10g per day in patients undergoing RIC allo-HCT.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02805075
Funding Statement
This work was supported in part by the Amy Strelzer Manasevit Award from the National Marrow Donor Program, the National Center for Advancing Translational Science, Clinical and Translational Science Awards KL2TR001083 and UL1TR001085 and the Society of Blood and Marrow Transplantation New Investigator Award (T.M.A.). F.B.T was supported in part by the National Science Foundation Graduate Research Fellowship. A.S.B. was supported by NCI KO8 CA184420, the Amy Strelzer Manasevit Award, a Damon Runyon Clinical Investigator Award, and the V Foundation scholar award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants meeting eligibility criteria were informed about the study and required to provide written informed consent under IRB #37979 (PI: Andrew Rezvani) prior to undergoing study-related procedures; patients not receiving FOS had consented to have their stool and blood samples collected under IRB #8903 (PI: David Miklos). The protocol and informed consent documents were reviewed and approved by the Stanford human subjects review board and the Stanford Cancer Institute. The study was performed in accordance with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data not included in the manuscript will be available by request to the corresponding authors. All metagenomic data will be uploaded to the SRA.
